CIRM handed Fate Therapeutics a $15 million grant on September 25 to fund RECLAIM-LN, the company’s Phase 2 trial of FT819 in lupus nephritis, a disease where kidney involvement affects a substantial share of systemic lupus patients and where standard-of-care regimens still leave many patients progressing toward dialysis or transplant. The grant does not change what the trial must prove, but it meaningfully extends the runway for a program built on an off-the-shelf CAR T-cell platform that has never had to rely on a single donor per patient.
FT819 is an allogeneic CAR T-cell therapy derived from induced pluripotent stem cells, designed to be manufactured at scale and administered without the weeks-long wait of autologous cell production. Earlier clinical data from the first four systemic sclerosis patients treated with FT819 showed signs of clinical activity, with a tolerability profile that did not require intensive conditioning chemotherapy, a meaningful practical difference from conventional CAR T approaches, since heavy lymphodepletion is one of the barriers limiting those therapies to specialized centers. Whether the same holds across lupus nephritis patients in RECLAIM-LN is precisely what the Phase 2 data will need to show.
The competitive context matters here. The lupus nephritis treatment field is not empty: obinutuzumab received FDA approval in October 2025 for adult patients with active lupus nephritis receiving standard therapy, and voclosporin and belimumab hold earlier approvals in the indication. Fate is asking whether a CAR T-cell approach can reach patients who fail or cannot tolerate those options, and whether “off-the-shelf” delivery makes that feasible outside academic transplant centers. The CIRM grant signals institutional confidence in that question, but it is not an answer.
The trial design and enrollment pace of RECLAIM-LN will now define whether the $15 million accelerates a clean dataset or simply sustains a slow one. Watch for the protocol’s conditioning regimen requirements: if Fate can replicate the lighter-lymphodepletion approach seen in the SSc data, that will be the result that actually reshapes how the field thinks about CAR T in autoimmune kidney disease.
Source link: https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/fate-20260925.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
